This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symptoms, and reduces mucosal antibody production.
Age range
18 Years – 49 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Nasal Mucosal secretome (AUC)
Timeframe: Day 0 to Day 7
Gene Expression (AUC)
Timeframe: Day 0 to Day 7
Virus Quantity (AUC)
Timeframe: Day 0 to Day 7
Nasal Neutrophils (AUC)
Timeframe: Day 0 to Day 7
Nasal Viral Antibodies (AUC)
Timeframe: Day 0 to Day 7
Blood Viral Antibodies (AUC)
Timeframe: Day 0 to Day 7